April 30, 2017
Recommended Topic Related To:


"The U.S. Food and Drug Administration today expanded the approved use of the CoreValve System to treat certain patients who have previously had a tissue aortic valve replacement and are in need of a second one.

This first-of-its-kind use is"...



How Supplied


Abciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications

  • in patients undergoing percutaneous coronary intervention
  • in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours

Safety and efficacy of Abciximab use in patients not undergoing percutaneous coronary intervention have not been established.

Abciximab is intended for use with aspirin and heparin and has been studied only in that setting, as described in Clinical Studies.


The safety and efficacy of Abciximab have only been investigated with concomitant administration of heparin and aspirin as described in Clinical Studies.

In patients with failed PCIs, the continuous infusion of Abciximab should be stopped because there is no evidence for Abciximab efficacy in that setting.

In the event of serious bleeding that cannot be controlled by compression, Abciximab and heparin should be discontinued immediately.

The recommended dosage of Abciximab in adults is a 0.25 mg/kg intravenous bolus administered 10-60 minutes before the start of PCI, followed by a continuous intravenous infusion of 0.125 μg/kg/min (to a maximum of 10 μg/min) for 12 hours.

Patients with unstable angina not responding to conventional medical therapy and who are planned to undergo PCI within 24 hours may be treated with an Abciximab 0.25.mg/kg intravenous bolus followed by an 18- to 24-hour intravenous infusion of 10 μg/min, concluding one hour after the PCI.

Instructions For Administration

  1. Parenteral drug products should be inspected visually for particulate matter prior to administration. Preparations of Abciximab containing visibly opaque particles should NOT be used.
  2. Hypersensitivity reactions should be anticipated whenever protein solutions such as Abciximab are administered. Epinephrine, dopamine, theophylline, antihistamines and corticosteroids should be available for immediate use. If symptoms of an allergic reaction or anaphylaxis appear, the infusion should be stopped and appropriate treatment given (see WARNINGS: Allergic Reactions).
  3. As with all parenteral drug products, aseptic procedures should be used during the administration of Abciximab.
  4. Withdraw the necessary amount of Abciximab for bolus injection into a syringe. Filter the bolus injection using a sterile, non-pyrogenic, low protein-binding 0.2 or 5 μm syringe filter (Millipore SLGV025LS or SLSV025LS or equivalent).
  5. Withdraw the necessary amount of Abciximab for the continuous infusion into a syringe. Inject into an appropriate container of sterile 0.9% saline or 5% dextrose and infuse at the calculated rate via a continuous infusion pump. The continuous infusion should be filtered either upon admixture using a sterile, non-pyrogenic, low protein-binding 0.2 or 5 μm syringe filter (Millipore SLGV025LS or SLSV025LS or equivalent) or upon administration using an in-line, sterile, non-pyrogenic, low protein-binding 0.2 or 0.22 μm filter (Abbott #4524 or equivalent). Discard the unused portion at the end of the infusion.
  6. No incompatibilities have been shown with intravenous infusion fluids or commonly used cardiovascular drugs. Nevertheless, Abciximab should be administered in a separate intravenous line whenever possible and not mixed with other medications.
  7. No incompatibilities have been observed with glass bottles or polyvinyl chloride bags and administration sets.


Abciximab (ReoPro®) 2 mg/mL is supplied in 5 mL vials containing 10 mg (NDC 0002-7140-01).

Vials should be stored at 2 to 8 °C (36 to 46 °F). Do not freeze. Do not shake. Do not use beyond the expiration date. Discard any unused portion left in the vial.

Manufactured by: Janssen Biologics B.V. Leiden, The Netherlands, U.S. License Number: 1865. Distributed by: Eli Lilly and Company, Indianapolis, IN 46285. Revision Date: November 2013

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 4/3/2017

How Supplied

Additional ReoPro Information

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Heart Health

Get the latest treatment options.

Atrial Fibrillation Quiz